Evidence map›Paper›PMID 25766984›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2015

A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses.

Diana Kouiavskaia, Zhaochun Chen, Eugenia Dragunsky, Olga Mirochnitchenko, Robert Purcell, Konstantin Chumakov

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Non-lytic spread of poliovirus requires the nonstructural protein 3CD.bioRxiv : the preprint server for biology · 2024
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Diana KouiavskaiaCenter for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Building 52, Room 1126, Silver Spring, MD 20993-0002, USA.
Zhaochun ChenNational Institute of Allergy and Infectious Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Eugenia DragunskyCenter for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Building 52, Room 1126, Silver Spring, MD 20993-0002, USA.
Olga MirochnitchenkoCenter for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Building 52, Room 1126, Silver Spring, MD 20993-0002, USA.
Robert PurcellNational Institute of Allergy and Infectious Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Konstantin ChumakovCenter for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Building 52, Room 1126, Silver Spring, MD 20993-0002, USA. Electronic address: konstantin.chumakov@fda.hhs.gov.
Center for Biologics Evaluation and Research · USNational Institutes of Health · US

Funding

Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

backgroundDevelopment of anti-poliovirus therapies to complement vaccination is an urgent priority. A number of antiviral drugs are in development. Recently we have developed human monoclonal antibodies that could be used for treatment of chronically infected individuals and emergency response to potential reappearance of polioviruses after eradication.

objectiveThe aim of this study was to characterize neutralizing activity of anti-poliovirus monoclonal antibody A12 against wild type, vaccine-derived, and drug-resistant poliovirus strains, evaluate in vivo pre- and post-exposure protective properties of the antibody against polioviruses of serotypes 1 and 2, and to determine whether it interferes with response to immunization with poliovirus vaccine. STUDY

designImmunogenicity studies were performed in CD1 mice. Poliovirus neutralizing titers were determined in poliovirus microneutralization assay. Poliovirus immunization-challenge experiments were performed in poliovirus-susceptible TgPVR21 mice.

resultsWe show that monoclonal antibody A12 effectively neutralizes in vitro a broad range of type 1 and type 2 wild and vaccine-derived polioviruses, provides effective pre- and post-exposure protection of TgPVR21 mice from challenge with a lethal dose of poliovirus. Treatment of animals with the antibody concurrent with IPV immunization does not prevent immune response to the vaccine.

conclusionsAnti-poliovirus antibody A12 effectively neutralizes a range of wild and VDPV strains and protectstransgenic mice susceptible to poliovirus against lethal challenge upon pre- and post-exposure administration. This suggests that the antibodies could be used in combination with drugs and/or vaccine to improve their efficacy and prevent emergence of resistant variants, and provides a justification for initiating their clinical evaluation.

Indexed as

Post-Exposure ProphylaxisAnimalsAntibodies, MonoclonalAntibodies, NeutralizingDrug Resistance, ViralHumansMiceNeutralization TestsPan troglodytesPoliomyelitisPoliovirusPre-Exposure ProphylaxisVaccinationAntibodies, MonoclonalAntibodies, NeutralizingAntiviral therapyChronic virus excretorsDrug-resistanceEmergency prophylaxisPolio eradication

Identifiers

PMID25766984
PMCPMC4378240
OpenAlexW1970207638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.